Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
| 7.88 | |
| 7.14 | |
| - | |
| 8.25 | |
| 7.14 | |
| 2.09-14.84 | |
| 560 M | |
| 71 071 K | |
| 409 K | |
| -0.35 | |
| 0.074 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE:LLY), for example. The last time I mentioned LLY, I said, “Oversold shares of Eli ...
To understand the allure of buying the best stocks under $10, it’s a good idea to go back to basics. A stock’s price reflects how much you pay for one dollar of a company’s earnings. So, investo...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
